CurrentHealth NetPolicy CP.MP.180

Implantable Hypoglossal Nerve Stimulation (PDF)

Defines medical necessity criteria for implantable hypoglossal (upper airway) nerve stimulation systems (Inspire, Genio) for treatment of moderate to severe obstructive sleep apnea (OSA), device-specific eligibility, contraindications, and requirement that DISE is medically necessary when used to evaluate appropriateness.

Policy Summary

PayerHealth Net

PolicyImplantable Hypoglossal Nerve Stimulation (PDF)

Policy CodePolicy CP.MP.180

Change TypeMaterial updates to device criteria and added Genio; DISE requirement added

Effective Date

Next Review Date

Key ActionSpecify device requested (Inspire® or Genio®) and demonstrate all device-specific eligibility criteria and absence of listed contraindications in prior authorization submission

SourceLink

POLICY UPDATE CHANGES

Added criteria II stating DISE is medically necessary when completed to evaluate appropriateness of a hypoglossal nerve stimulation device.

Updated Inspire criteria BMI to ≤ 40 kg/m2 and adjusted AHI thresholds formatting and ranges (e.g., AHI ≥15 and ≤100); added rhabdomyolysis as a contraindication.

Added Genio® System criteria (device-specific) including BMI ≤32 kg/m2, cricomental space, non-supine AHI requirement, and device contraindications.

Added CPT codes 64582, 64583, 64584, and later 64568 and 64569 for Inspire V

Changed wording in Criteria I from 'all of the following criteria' to 'either of the following criteria.'

2Device-specific coverage pathways

variedAHI eligibility categories

Contraindication items

Coverage Summary

This policy defines medical necessity for implantable hypoglossal (upper airway) nerve stimulation systems (UAS) — specifically the Inspire® and Genio® devices — as a covered_with_criteria therapy for select patients with moderate to severe obstructive sleep apnea (OSA) who have failed or are intolerant of positive airway pressure (PAP) therapy. Device-specific eligibility requirements include documented polysomnography (PSG) within 24 months of first consultation, specified age and body mass index (BMI) thresholds (Inspire: BMI ≤ 40 kg/m2; Genio: BMI ≤ 32 kg/m2), and device-specific AHI ranges (Inspire adults: AHI ≥ 15 and ≤ 100; Genio: AHI ≥ 15 and ≤ 65; special pediatric/Down syndrome provisions apply in the Inspire pathway).

Drug-induced sleep endoscopy (DISE) is required and is specified as medically necessary when completed to evaluate appropriateness of a hypoglossal nerve stimulation device. The policy also lists contraindications and conditions that must be absent for coverage (for example, combined central/mixed apneas > 25% of total AHI, anatomic findings such as complete concentric collapse of the soft palate, incompatible implanted devices, MRI needs beyond MR-conditional labeling, pregnancy, neurological compromise, and rhabdomyolysis).

Quick thresholds and facts

Device-specific coverage pathways2

AHI eligibility categories noteAHI thresholds vary by device and subgroup (see device-specific thresholds)

Contraindication items countMultiple contraindications

Inspire - AHI thresholdAHI ≥ 15 and ≤ 100

Inspire - BMI thresholdBMI ≤ 40 kg/m2

Genio - AHI thresholdAHI ≥ 15 and ≤ 65

Genio - BMI thresholdBMI ≤ 32 kg/m2

I. Medical necessity for implantable hypoglossal nerve neurostimulation

II. Drug-induced sleep endoscopy (DISE)

Covered when completed to evaluate appropriateness of a hypoglossal nerve stimulation device:

DISE is medically necessary when completed to evaluate the appropriateness of a hypoglossal nerve stimulation device

Provider action and prior authorization requirements

Documentation Required

PSG timing documentation

Document that a diagnostic polysomnography (PSG) used for selection was performed within 24 months of the patient’s first consultation for hypoglossal nerve stimulator implantation.

Documentation Required

AHI and BMI documentation

Document the patient’s apnea-hypopnea index (AHI) and body mass index (BMI) values and confirm they meet the device-specific thresholds for the requested system (Inspire: AHI and BMI per Inspire criteria; Genio: AHI and BMI per Genio criteria).

Coding

Referenced CPT codesCPT

42975	Drug-induced sleep endoscopy, with dynamic evaluation of velum, pharynx, tongue base, and larynx for evaluation of sleep-disordered breathing, flexible, diagnostic
64582	Open implantation of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array
64583	Revision or replacement of hypoglossal nerve neurostimulator array and distal respiratory sensor electrode or electrode array, including connection to existing pulse generator
64584	Removal of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array
64568	Open implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator
64569	Revision or replacement of cranial nerve (eg, vagus nerve) neurostimulator electrode array, including connection to existing pulse generator

Referenced HCPCS / supply codesHCPCS

C1767	Generator, neurostimulator (implantable), nonrechargeable
C1778	Lead, neurostimulator (implantable)
C1787	Patient programmer, neurostimulator
L8679	Implantable neurostimulator, pulse generator, any type
L8680	Implantable neurostimulator electrode, each
L8681	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension

Background, evidence, and definitions

Two device options are addressed: the Inspire® Upper Airway Stimulation system (a unilateral implanted pulse generator with sensing lead and external programmers) and the Genio® System (a bilateral, battery-free implantable stimulator with an external wearable controller). Evidence from uncontrolled studies and registries demonstrates clinically meaningful reductions in AHI and improvements in symptoms and quality of life (for example, meta-analysis reports ~50–57% reductions in AHI; ADHERE registry median AHI decreased from 34 to 7 with median ESS reduction from 12 to 7 at 12 months). The DREAM trial for Genio reported a median 70.8% reduction in AHI, a 63.5% AHI responder rate, and 82% of participants achieving AHI < 15.

Limitations of the evidence include a relative lack of large randomized comparative trials and longer-term randomized data; ongoing device and procedural refinements mean additional research is needed to refine selection criteria, long-term outcomes, and comparative effectiveness.

Key evidence highlights

ADHERE registryMedian AHI reduced from 34 to 7; median ESS reduced from 12 to 7 at 12 months

Meta-analysis (AHI reduction)50–57% reductions in AHI in uncontrolled studies

DREAM trial (Genio)63.5% AHI responder rate; median 70.8% AHI reduction; 82% achieved AHI < 15

Medicare local coverage determinations

Effective Date	Name	LCD Number/Type
2020-03-15
Hypoglossal nerve stimulation for the treatment of obstructive sleep apnea
L38310 / LCD
2020-03-15
Billing and Coding: Hypoglossal nerve stimulation for the treatment of obstructive sleep apnea (Article)
A57948 / LCD

Revision history

08/24added

Added DISE criteria: drug-induced sleep endoscopy (DISE) is medically necessary when completed to evaluate the appropriateness of a hypoglossal nerve stimulation device (Criteria II).

11/24revised (material)

Updated Inspire criteria AHI formatting to change I.C.3.a from >15 and <100 to ≥15 and ≤100; added contraindication for rhabdomyolysis (I.D.8).

11/25added (material)

Added Genio® System criteria: device-specific pathway including BMI ≤ 32 kg/m2, cricomental space requirement, non-supine AHI positional requirement, and device contraindications (Criteria I.B added).

Policy Summary

PayerHealth Net

PolicyImplantable Hypoglossal Nerve Stimulation (PDF)

Policy CodePolicy CP.MP.180

Change TypeMaterial updates to device criteria and added Genio; DISE requirement added

Effective Date

Next Review Date

Key ActionSpecify device requested (Inspire® or Genio®) and demonstrate all device-specific eligibility criteria and absence of listed contraindications in prior authorization submission

SourceLink

On This Page

Documentation Required

PAP therapy failure/intolerance documentation

Document attempts and reasons for PAP failure, refusal, or intolerance. Include objective PAP usage data (hours/night and nights/week) consistent with the policy definitions (e.g., >4 hours/night; >5 nights/week or at least five nights/week as applicable) or documentation of return/nonuse of PAP equipment.

Prior Authorization

Device-specific request specification

Specify the device requested (Inspire® or Genio®) in the prior authorization request and demonstrate that all device-specific eligibility criteria are met and that none of the device-specific contraindications apply.

Documentation Required

Contraindication assessment

Document assessment demonstrating absence of listed contraindications, including proportion of central/mixed apneas, anatomical findings that would compromise UAS (e.g., complete concentric collapse of the soft palate), presence of incompatible implanted devices, MRI requirements beyond MR-conditional labeling, pregnancy or plans for pregnancy, rhabdomyolysis, and conditions compromising neurological control of the upper airway.

Documentation Required

DISE when used for evaluation

When drug-induced sleep endoscopy (DISE) is performed to evaluate candidacy for hypoglossal nerve stimulation, document the procedure and include the associated procedure code reference.

CPT 42975

Glossary — key definitions used in this policy:

AHI (Apnea-Hypopnea Index): Apnea-hypopnea index — the metric used to classify OSA severity and apply device-specific AHI thresholds.

PSG (Polysomnography): Polysomnography — an overnight sleep study required to document OSA and meet timing criteria (performed within 24 months of first consultation for implant).

DISE (Drug-Induced Sleep Endoscopy): Drug-induced sleep endoscopy — an endoscopic evaluation performed under sedation and is medically necessary when completed to evaluate the appropriateness of a hypoglossal nerve stimulation device.

Cricomental space: Distance between the neck and the bisection of a line from the chin to the cricoid membrane when the head is in a neutral position; a positive cricomental space (≥ 0 cm) is a Genio-specific criterion.

11/24 through 11/25revised (material)

Multiple revisions updated Inspire BMI threshold to ≤40 kg/m2 and adjusted age/AIH subgroup formatting and ranges (e.g., AHI thresholds and age-specific criteria) as part of iterative annual reviews and edits aligning with FDA updates and adding Genio criteria.

11/21 to 06/25 (coding updates)coding (non-material)

Coding table updates across multiple revisions: added CPT codes 64582, 64583, 64584 (11/22) and later added Inspire V codes 64568 and 64569 (06/25); other coding table adjustments occurred in 11/21–11/22 logs.

01/26clarified (non-material)Latest

Wording clarification in Criteria I changed verbiage from 'all of the following criteria' to 'either of the following criteria.'